Please find enclosed unaudited financial results for the quarter and half year ended September 30, 2026 along with the limited review report.

Pfizer Limited The Capital, 1802/1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274 November 3, 2026 The Corporate Relationship Dept. The Listing Dept. BSE Limited The National Stock Exchange of India Ltd. 1st Floor, P.J.Towers Exchange Plaza, 5th Floor, Plot No. C/1, Dalal Street, Fort G Block Bandra-Kurla Complex, Bandra (E) Mumbai – 400 001 Mumbai – 400 051 Scrip Code: 500680 Scrip Symbol: PFIZER Dear Sir / Madam, Sub: Outcome of Board Meeting – Unaudited Financial Results for the quarter and half year ended September 30, 2026. Ref.: Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026, which were approved by the Board of Directors of the Company at its meeting held today i.e., November 3, 2026, that commenced at 12.00 p.m. and concluded at 2.00 p.m. Please also find enclosed herewith the Limited Review Report issued by the Statutory Auditors, B S R & Co. LLP, in respect of the said Unaudited Financial Results. We request you to kindly take the above on record. Thanking you, Yours truly, For Pfizer Limited Prajeet Nair Director – Corporate Services & Company Secretary CIN: L24231MH1950PLC008311 Email ID: contactus.india@pfizer.com Website: www.pfizerltd.co.in BS R & Co. LLP 14th Floor, Central B Wing and North C Wing Nesco IT Park 4, Nesco Center Western Express Highway Chartered Accountants Goregaon (East), Mumbai - 400 063, India Telephone: +91 (22) 6257 1000 Fax: +91 (22) 6257 1010 Limited Review Report on unaudited financial results of Pfizer Limited for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To the Board of Directors of Pfizer Limited 1. We have reviewed the accompanying Statement of unaudited financial results of Pfizer Limited (hereinafter referred to as "the Company") for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 ("the Statement"). 2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For B S R & Co. LLP Chartered Accountants Firm's Registration No.:101248W/W-100022 Sreeja Marar Partner Mumbai Membership No.: 111410 03 November 2026 UDIN:26111410OUBCAF9635 Registered Office: BS R & Co. (a partnership firm with Registration No. BA61223) converted into BS R & Co. LLP (a 14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013 Center, Western Express Highway, Goregaon (East), Mumbai -400063 Page 1 of 1 &Pfizer Pfizer Limited The Capital, 1802/1901, Plot No. C -70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax: +91 22 2654 0274 Statement of Unaudited Financial Results for the Quarter and Half year ended 30 September 2026 {!I! in crore except earnings per share) 3 months ended 3 months ended Corresponding 3 Year to date Year to date Previous year 30/09/2026 30/06/2026 months ended in figures for six figures for six ended Particulars the previous year months ended months ended 31/03/2026 30/09/2025 30/09/2026 30/09/2025 Unaudited Unaudited Unaudited Unaudited Unaudited Audited 1 income (a) Revenue from operations 726.86 653.17 642.34 1,380.03 1,245.39 2,519.65 (b) Other income 47.33 44.84 41.85 92.17 109.02 187.95 Total income 774.19 698.01 684.19 1,472.20 1,3S4.41 2,707.60 2 Expenses (a) Cost of materials consumed 56.51 105.02 70.00 161.53 158.69 309.51 (b) Purchases of stock-in-trade 206.28 182.89 221.27 389.17 345.55 608.39 (c) Changes in inventory of finished goods, work-in-progress and stock-in-trade 34.48 (47.80) (63.32) (13.32) (65.06) (33.59) (d) Employee benefits expense 91.43 82.08 94.67 173.51 190.49 367.97 (e) Finance costs 3.35 1.46 2.13 4.81 5.38 9.48 (f) Depreciation and amortization expense 14.41 14.26 14.28 28.67 28.69 57.73 (g) Other expenses 76.96 83.42 89.79 160.38 175.77 363.28 Total expenses 483.42 421.33 428.82 904.75 839.51 1,682.77 3 Profit before tax and exceptional items (l -2) 290.77 276.68 255.37 567.45 514.90 1,024.83 4 Exceptional items (Refer Note 4) 132.06 - 132.06 - (49.16) 5 Profit before tax (3 + 4) 422.83 276.68 255.37 699.51 514.90 975.67 6 Tax expense (a) Current tax 107.59 70.93 65.49 178.52 132.88 257.52 (b) Deferred tax 1.99 1.28 0.86 3.27 1.25 (4.28) 7 Net profit for the period/year (5 -6) 313.25 204.47 189.02 517.72 380.77 722.43 8 Other comprehensive income (a) Items that will not be reclassified subsequently to profit or loss (0.72) (0.72) (1.22) (1.44) (2.45) 5.11 (b) Income tax related to items that will not be reclassified to profit or loss 0.18 0.18 0.31 0.36 0.62 (1.27) Other comprehensive income, net of taxes (0.54) (0.54) (0.91) (1.08) (l.83) 3.84 9 Total comprehensive income for the period/ year (7 + 8) 312.71 203.93 188.11 516.64 378.94 726.27 10 Paid-up equity share capital (Face value per share U0) 45.75 45.75 45.75 45.75 45.75 45.75 . . . . . 11 Other equity 4,157.15 12 Earnings per share -Basic and Diluted (of U0/-each)# Computed on the basis of net profit for the period/year 68.47 44.69 41.32 113.17 83.23 157.92 # Earnings per share -Basic and Diluted before Exceptional items 47.09 44.69 41.32 91.80 83.23 165.88 *Not annualised CIN: L24231 M H 1950PLC008311 Email ID: contactus 1nd1a@pf1zer com Website: www pfizerltd co In Statement of Assets and Liabilities as at 30 September 2026 (~ in crore) Particulars As at As at 30Seo 2026 31 March 2026 Unaudited Audited ASSETS Non-current assets Property, plant and equipment 267.47 136.13 Capital work-in-progress 31.48 20.00 Goodwill 527.49 527.49 Other intangible asset [Showing first 8,000 characters — download PDF for full document]